HopeStage
Back to all studies
RecruitingNCT06494904

Standard or high-dose buprenorphine start in emergency departments

About this titleRead the official source — NCT06494904
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Oakland and 4 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: December 6, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
360
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06494904
Official title
Show the full official title

ED-Initiated Standard Versus High Dose Buprenorphine Induction

Recruitment & locations

Currently recruiting

Oakland · San Leandro · Portland

2 more locations
  • Camden
  • Salt Lake City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Does this study involve medication?

Yes. The study involves medication, including Buprenorphine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies